# Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions

> **NCT01282801** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Venlafaxine Hydrochloride
- **DRUG:** Effexor® XR

## Key facts

- **NCT ID:** NCT01282801
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282801, "Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01282801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*